Market for companion diagnostics set to grow

Kathy Mahdoubi | | Health Imaging | Molecular Imaging

Diagnostic tests that inform selection and efficacy of therapy go by a few different names, including theranostics and companion diagnostics, but whatever you call them, the market for these tests is expected to grow at a compound annual growth rate of 4.9 percent and non-small cell lung cancer (NSCLC) tests are expected to account for 55 percent of market value this year, according to a report published this month by GlobalData.

Human epidermal growth factor receptor 2 (HER2) tests are more numerous, but evaluating for mutations in NSCLC, a more expensive test, was ultimately deemed the biggest financial driver in the market.

The dominant players in the market are pharmaceutical companies Roche and Qiagen. Other names included Ventana, Dako and Leica. HER2 tests appear to present the most competition in the market.

Areas of market growth included the U.S., France, Germany, Italy, Spain, UK, Brazil, Japan, China, and India. However the American and European markets are growing the slowest while Brazil and China are showing the most growth.

A key factor of growth in developing markets was patient access to laboratory testing and an increase in professional pathology services.

Kathy Mahdoubi

Related Content

Researchers receive grant worth millions to develop portable PET scanner
Why is the US still dependent on foreign medical isotope production?
Downed high-flux reactor could restart sooner than anticipated
Some nuc med departments are already feeling the strain of the isotope shortage
NorthStar opens facility to assist with development and distribution of vital radioisotopes
Lizard saliva could be key to spotting elusive pancreatic tumors

Around the web

Cardiovascular Business
Positron partners with Upbeat Cardiology Solutions to improve cardiac PET/CT access

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services. 

Cardiovascular Business
Global shortage of nuclear imaging isotopes may be over

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

Cardiovascular Business
‘A huge win’: CMS significantly increases Medicare payments for cardiac CT

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.